Cargando…
Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection
The antibody response to SARS-CoV-2 has not yet fully defined, but the availability of sensitive and specific serological assays is crucial to observe the presence of specific antibodies against the human receptor binding domain (S-RBD) and high specificity ACE-2-binding antibodies or neutralizing a...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313542/ https://www.ncbi.nlm.nih.gov/pubmed/34339963 http://dx.doi.org/10.1016/j.intimp.2021.108013 |
_version_ | 1783729371076362240 |
---|---|
author | Tomassetti, Flaminia Nuccetelli, Marzia Sarubbi, Serena Gisone, Francesca Ciotti, Marco Spinazzola, Francesco Ricotta, Cristina Cagnoli, Monica Borgatti, Monica Iannetta, Marco Andreoni, Massimo Calugi, Graziella Pieri, Massimo Bernardini, Sergio |
author_facet | Tomassetti, Flaminia Nuccetelli, Marzia Sarubbi, Serena Gisone, Francesca Ciotti, Marco Spinazzola, Francesco Ricotta, Cristina Cagnoli, Monica Borgatti, Monica Iannetta, Marco Andreoni, Massimo Calugi, Graziella Pieri, Massimo Bernardini, Sergio |
author_sort | Tomassetti, Flaminia |
collection | PubMed |
description | The antibody response to SARS-CoV-2 has not yet fully defined, but the availability of sensitive and specific serological assays is crucial to observe the presence of specific antibodies against the human receptor binding domain (S-RBD) and high specificity ACE-2-binding antibodies or neutralizing antibodies (NT) in response to vaccines. Indeed, these peculiar antibodies should prevent viral interaction between RBD and Angiotensin-Converting Enzyme 2 (ACE2) receptor, located on surface of host cells. In this study, 72 samples from 37 hospitalized COVID-19 patients and 35 not-hospitalized patients were analyzed longitudinally. The detection of S-RBD and NT antibodies was carried out using CLIA tests. Hospitalized patients showed elevated serum levels of S-RBD (97.22%) and NT (77.78%) antibodies, differently, not-hospitalized, who were paucisymptomatic or asymptomatic patients, showed lower serum levels of S-RBD (65.71%) and NT (38.14%) antibodies. The results suggest that the NT serum level is strongly related to disease severity (p < 0.001) and to the serum level of S-RBD antibodies (p < 0.0001). |
format | Online Article Text |
id | pubmed-8313542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83135422021-07-27 Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection Tomassetti, Flaminia Nuccetelli, Marzia Sarubbi, Serena Gisone, Francesca Ciotti, Marco Spinazzola, Francesco Ricotta, Cristina Cagnoli, Monica Borgatti, Monica Iannetta, Marco Andreoni, Massimo Calugi, Graziella Pieri, Massimo Bernardini, Sergio Int Immunopharmacol Article The antibody response to SARS-CoV-2 has not yet fully defined, but the availability of sensitive and specific serological assays is crucial to observe the presence of specific antibodies against the human receptor binding domain (S-RBD) and high specificity ACE-2-binding antibodies or neutralizing antibodies (NT) in response to vaccines. Indeed, these peculiar antibodies should prevent viral interaction between RBD and Angiotensin-Converting Enzyme 2 (ACE2) receptor, located on surface of host cells. In this study, 72 samples from 37 hospitalized COVID-19 patients and 35 not-hospitalized patients were analyzed longitudinally. The detection of S-RBD and NT antibodies was carried out using CLIA tests. Hospitalized patients showed elevated serum levels of S-RBD (97.22%) and NT (77.78%) antibodies, differently, not-hospitalized, who were paucisymptomatic or asymptomatic patients, showed lower serum levels of S-RBD (65.71%) and NT (38.14%) antibodies. The results suggest that the NT serum level is strongly related to disease severity (p < 0.001) and to the serum level of S-RBD antibodies (p < 0.0001). Elsevier B.V. 2021-10 2021-07-27 /pmc/articles/PMC8313542/ /pubmed/34339963 http://dx.doi.org/10.1016/j.intimp.2021.108013 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Tomassetti, Flaminia Nuccetelli, Marzia Sarubbi, Serena Gisone, Francesca Ciotti, Marco Spinazzola, Francesco Ricotta, Cristina Cagnoli, Monica Borgatti, Monica Iannetta, Marco Andreoni, Massimo Calugi, Graziella Pieri, Massimo Bernardini, Sergio Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection |
title | Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection |
title_full | Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection |
title_fullStr | Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection |
title_full_unstemmed | Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection |
title_short | Evaluation of S-RBD and high specificity ACE-2-binding antibodies on SARS-CoV-2 patients after six months from infection |
title_sort | evaluation of s-rbd and high specificity ace-2-binding antibodies on sars-cov-2 patients after six months from infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313542/ https://www.ncbi.nlm.nih.gov/pubmed/34339963 http://dx.doi.org/10.1016/j.intimp.2021.108013 |
work_keys_str_mv | AT tomassettiflaminia evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT nuccetellimarzia evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT sarubbiserena evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT gisonefrancesca evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT ciottimarco evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT spinazzolafrancesco evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT ricottacristina evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT cagnolimonica evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT borgattimonica evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT iannettamarco evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT andreonimassimo evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT calugigraziella evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT pierimassimo evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection AT bernardinisergio evaluationofsrbdandhighspecificityace2bindingantibodiesonsarscov2patientsaftersixmonthsfrominfection |